598.00
+7(+1.18%)
Currency In GBp
Address
Windrush Court
Oxford, OX4 6LT
United Kingdom of Great Britain and Northern Ireland
Phone
44 1865 783 000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
850
First IPO Date
December 13, 1996
| Name | Title | Pay | Year Born |
| Dr. Frank Mathias | Chief Executive Officer & Director | 1.11M | 1962 |
| Dr. Lucinda Crabtree Ph.D. | Chief Financial Officer & Director | 512,425 | 1979 |
| Ms. Sophia Bolhassan | Head of Investor Relations | 0 | N/A |
| Dr. Kyriacos Mitrophanous Ph.D. | Chief Innovation Officer | 0 | N/A |
| Mr. Thierry Cournez | Chief Operating Officer | 0 | N/A |
| Ms. Natalie Louise Walter | General Counsel & Company Secretary | 0 | 1973 |
| Ms. Lisa Doman | Chief People Officer | 0 | N/A |
| Mr. Mark Caswell | Site Head of UK Operations | 0 | N/A |
| Ms. Kati Hudson | Head of Intellectual Property and Contracts | 0 | N/A |
| Dr. Sebastien Ribault | Chief Business Officer | 0 | N/A |
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.